A Study of Prexasertib (LY2606368) in Combination With Ralimetinib in Participants With Advanced or Metastatic Cancer
The main purpose of this study is to evaluate the safety of the study drug prexasertib in combination with ralimetinib in participants with advanced or metastatic cancer.
Checked against the public recordLast updated Dec 14, 2018 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Treatment
- Study type
- Interventional
- Phase
- Phase 1
- Sponsor
- Eli Lilly and Company
- Interventions being studied
- Drug: prexasertib; Drug: ralimetinib
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Inclusion Criteria: * Advanced or metastatic cancer. * Able to swallow tablets. * For Part B, you will need to have colon cancer or non-small cell lung (NSCLC) cancer with KRAS and/or BRAF mutations. * Discontinued all previous treatments for cancer and recovered from the acute effects from the therapy. Exclusion Criteria: * Active infection (fungal, viral, or bacterial). * Active cancer in your brain or spinal cord. * Acute or chronic leukemia. * Serious heart condition. * Disease that requires immunosuppressant therapy. * Diagnosis of inflammatory bowel disease. * Major small bowel resection that interferes with your body's ability to absorb the oral medicine. * Participated in other clinical trials investigating prexasertib or ralimetinib. * Pregnant or breastfeeding. * Other pre-existing conditions or medical history which your doctor will explain to you.
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- Carolinas Medical CenterCharlotte, North Carolina
- Sarah Cannon Research Institute SCRINashville, Tennessee
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.Cologne
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Dec 14, 2018. Always confirm current availability with the study team.